About Syncom Formulations (India) Ltd
Syncom Formulations (India) is a renowned name in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Currently Syncom manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers.
Founded
1988
CEO
ANKIT KEDARMAL BANKDA
Employees
2,122
HQ
Indore, India
Finished Products
1Tablets
₹592.17Cr2Injectables
₹92.43Cr3Others-Traded
₹77.30Cr4Plastic Grannuals
₹35.73Cr5Others
₹30.93Cr6Capsules
₹24.87Cr7Liquids
₹19.69Cr1–7 of 20
Raw Materials
1Cost of Material Consumed
₹278.03Cr2Others
₹117.64Cr3Packing Mtls.
₹80.28Cr4Granuals Purchase
₹38.59Cr5Other Purchase
₹27.69Cr6Paracetamol
₹23.21Cr7Stock in trade
₹20.71Cr1–7 of 13
About Syncom Formulations (India) Ltd
Syncom Formulations (India) is a renowned name in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Currently Syncom manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers.
Founded:1988
CEO:ANKIT KEDARMAL BANKDA
Employees:2,122
HQ:Indore, India
Finished Products
1Tablets
₹592.17Cr2Injectables
₹92.43Cr3Others-Traded
₹77.30Cr4Plastic Grannuals
₹35.73Cr5Others
₹30.93Cr6Capsules
₹24.87Cr7Liquids
₹19.69Cr1–7 of 20
Raw Materials
1Cost of Material Consumed
₹278.03Cr2Others
₹117.64Cr3Packing Mtls.
₹80.28Cr4Granuals Purchase
₹38.59Cr5Other Purchase
₹27.69Cr6Paracetamol
₹23.21Cr7Stock in trade
₹20.71Cr1–7 of 13
Price Performance & Market EventsPrice Performance
Loading chart data…
Key Metrics
Trading & valuation snapshot
52W High
₹22
52W Low
₹10
Volume28.99M
Avg VolumeN/A
Beta1.38
Dividend Yield0.00%
Key Financial Ratios
Profitability, leverage & efficiency at a glance
P/E Ratio
23.51x
Valuation
P/B Ratio
4.85x
Valuation
EPS
₹0.91
Valuation
Dividend Yield
0.00%
Valuation
ROE
18.42%
Profitability
ROCE
24.46%
Profitability
Revenue by Segment
Contribution & growth by business line
Pharmaceutical Drugs & Formulations
+79.4%97.5%
₹470.27 Cr
Trading of Commodities
-22.9%1.7%
₹8.26 Cr
Renting of Property
-2.7%0.8%
₹3.91 Cr
Geographical Revenue Split
Domestic vs international exposure
Domestic
15.5%
International
84.5%
Outside India84.5%
In India15.5%
Strategic Relations
Collaborations, joint ventures & subsidiaries
No collaborations data available.
Forensic Metrics
Financial health & earnings-quality indicators
Revenue Quality
N/A
Days Sales Outstanding
Leverage
0.00x
Debt-to-Equity
Earnings Quality
N/A
Cash Conversion Ratio
Efficiency
N/A
Asset Turnover
Earnings Quality
N/A
Accruals Ratio
Profitability
N/A
Gross Margin
Growth
27.5%
Sales Growth
These metrics are derived from available financial disclosures and market data. Use them together with company filings and qualitative analysis before making decisions.